Roche teams with Flare Ther­a­peu­tics on tran­scrip­tion fac­tors

Roche is align­ing with Flare Ther­a­peu­tics to work on small mol­e­cules for can­cer by go­ing af­ter tran­scrip­tion fac­tor tar­gets, the com­pa­nies said Tues­day morn­ing. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER